Peritoneal metastasis in locally advanced colon cancer has a poor prognosis from 3 years post surgical resection. Dr Alvaro Arjona-Sanchez (Institute of Biomedical Research IMIBIC, University Hospital Reina Sofia, Cordoba, Spain) joins touchONCOLOGY to discuss the HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally advanced colon cancer.
The abstract entitled ‘Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): A randomized phase III study‘ Abstract 314O, was presented at European Society for Medical Oncology (ESMO) 2022.
Questions:
- What is the incidence and prognosis of peritoneal metastasis in locally advanced colon cancer, and what are the unmet needs in its treatment? (0:15)
- What controversy exists around the use of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) in these patients? (0:42)
- What were the aims, design and eligibility criteria of your study? (1:16)
- What were the study findings, and which patients were most likely to benefit? (2:03)
- What questions remain unanswered about HIPEC and what future studies are planned? (2:41)
Disclosures: Alvaro Arjona-Sanchez has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
